VIENTIANE, LAO PEOPLE’S DEMOCRATIC REPUBLIC, March 3, 2023 — BigBearPharma has announced that all of its production facilities have obtained the Good Manufacturing Practice (GMP) certificate issued by the Food and Drug Department (FDD) of Laos.
The investor team of BigBear Pharma conducted an inspection tour of the investment environment in Laos in 2021, and officially launched the investment and construction of production facilities in the same year. After one year of construction and refinement, the company was granted the GMP certification by the Lao regulatory authority on January 16, 2023. This approval paves the way for BigBear Pharma’s next-step product marketing authorization. It is worth noting that the quality system adopted by the Lao Food and Drug Department is aligned with the EU GMP standards.
The CEO of BigBear Pharma stated, “Thanks to the hard work and dedication of all employees as well as the support from investors, our production units have completed construction and acceptance inspection as scheduled, and simultaneously obtained the Pharmaceutical Manufacturing License issued by the Lao regulatory authority. As a new-generation pharmaceutical company in Laos, we are equipped with state-of-the-art production lines and clean workshops. In light of this, I am delighted that we boast strong competitiveness in Southeast Asia.”
Founded in 2021, BigBear Pharmaceutical features well-equipped infrastructure, including several independent production areas and associated packaging sections. As a new-generation pharmaceutical enterprise in Laos, it owns modern pharmaceutical formulation workshops capable of manufacturing major product categories such as tablets, capsules, chronic disease medications, and anti-cancer drugs. These products are designed to meet the demand for treating common diseases among patients in Asia, particularly in the Southeast Asian region.
Forward-Looking Statements
Within the scope permitted by applicable laws and regulations, statements containing words such as “plan”, “target”, “expect”, “forecast” and similar expressions in this press release constitute forward-looking statements. The forward-looking statements made herein are subject to numerous risks and uncertainties that could cause actual results to differ materially from those anticipated. Key factors contributing to such discrepancies include, but are not limited to, changes in regulatory and/or economic conditions, uncertainties surrounding clinical research results, various market risks, and other factors beyond the Company’s control.
